4559 — Zeria Pharmaceutical Co Share Price
0.000.00%
Last trade - 00:00- ¥102bn
- ¥121bn
- ¥76bn
- 92
- 63
- 94
- 97
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 10.08 | ||
| PEG Ratio (f) | 0.93 | ||
| EPS Growth (f) | 12.19% | ||
| Dividend Yield (f) | 2.51% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.2 | ||
| Price to Tang. Book | 2.29 | ||
| Price to Free Cashflow | 7.57 | ||
| Price to Sales | 1.23 | ||
| EV to EBITDA | 6.8 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 9.94% | ||
| Return on Equity | 9.22% | ||
| Operating Margin | 12% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 60,426.74 | 52,757.18 | 59,532.83 | 68,383.23 | 75,725.07 | 86,500 | 90,000 | 4.14% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +22.29 | -0.93 | +39.22 | +52.48 | +13.68 | +10.33 | +12.19 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Zeria Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the development of ethical drug business, consumer healthcare business and other business. The Company operates in two business segments. The Ethical Drug segment is engaged in the research, development, manufacture and sale of ethical drugs. The Consumer Healthcare segment is engaged in the manufacture, purchase and sale of over-the-counter (OTC) drugs, health foods, quasi drugs and cosmetics related to self-medication. The others include insurance agency business and real estate business, as well as various maintenance business such as purchasing and sale of promotional materials.
Directors
- Sachiaki Ibe CHM (76)
- Mitsuhiro Ibe PRE (49)
- Hirokazu Endo VPR (68)
- Makoto Kishimoto MDR (68)
- Hiroki Kato DSL (58)
- Kenji Kusano DSL (57)
- Yuki Okazawa DHR (56)
- Yoshihiro Hiraga OTH (64)
- Toshiaki Kawagoe OTH (60)
- Tetsuo Komori IND (73)
- Seiji Morimoto IND (70)
- Kikuo Nomoto IND (85)
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 22nd, 1955
- Public Since
- December 22nd, 1998
- No. of Shareholders
- 13,775
- No. of Employees
- 1,777
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 44,079,539
- Address
- 10-11, Nihombashi Kobuna-cho, CHUO-KU, 103-8351
- Web
- https://www.zeria.co.jp/
- Phone
- +81 336632351
- Auditors
- KPMG AZSA LLC
Upcoming Events for 4559
Similar to 4559
ASKA Pharmaceutical Holdings Co
Tokyo Stock Exchange
Astellas Pharma
Tokyo Stock Exchange
Astena Holdings Co
Tokyo Stock Exchange
CanBas Co
Tokyo Stock Exchange
CellSeed
Tokyo Stock Exchange
FAQ
What is the Zeria Pharmaceutical Co share price?
As of Today at 24:15 UTC, shares in Zeria Pharmaceutical Co are trading at ¥2,310. This share price information is delayed by 15 minutes.
How has the Zeria Pharmaceutical Co share price performed this year?
Shares in Zeria Pharmaceutical Co last closed at ¥2,310 and the price had moved by +12.79% over the past 365 days. In terms of relative price strength the Zeria Pharmaceutical Co share price has outperformed the Nikkei 225 Index by +18.87% over the past year.
What are the analyst and broker recommendations for Zeria Pharmaceutical Co?
The overall consensus recommendation for Zeria Pharmaceutical Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Zeria Pharmaceutical Co dividend yield?
The Zeria Pharmaceutical Co dividend yield is 1.95% based on the trailing twelve month period.
Does Zeria Pharmaceutical Co pay a dividend?
Last year, Zeria Pharmaceutical Co paid a total dividend of ¥45, and it currently has a trailing dividend yield of 1.95%.Looking ahead, the next dividend pay date is 2025-06-01.
When does Zeria Pharmaceutical Co next pay dividends?
We do not have data on when Zeria Pharmaceutical Co is to next pay dividends. The historic dividend yield on Zeria Pharmaceutical Co shares is currently 1.95%.
How do I buy Zeria Pharmaceutical Co shares?
To buy shares in Zeria Pharmaceutical Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Zeria Pharmaceutical Co?
As of the previous close price of ¥2,310, shares in Zeria Pharmaceutical Co had a market capitalisation of ¥102bn.
Where are Zeria Pharmaceutical Co shares listed?
Here are the trading details for Zeria Pharmaceutical Co:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4559
What kind of share is Zeria Pharmaceutical Co?
Based on an overall assessment of its quality, value and momentum Zeria Pharmaceutical Co is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Zeria Pharmaceutical Co share price forecast for 2025?
The analyst consensus target price for shares in Zeria Pharmaceutical Co is ¥3,009. That is 30.26% above the last closing price of ¥2,310.
Analysts covering Zeria Pharmaceutical Co currently have a consensus Earnings Per Share (EPS) forecast of ¥204 for the next financial year.
Find out moreWhat is the trend in the Zeria Pharmaceutical Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zeria Pharmaceutical Co. Over the past six months, its share price has outperformed the Nikkei 225 Index by +9.16%.
As of the last closing price of ¥2,310, shares in Zeria Pharmaceutical Co were trading +3.06% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Zeria Pharmaceutical Co PE Ratio?
The Zeria Pharmaceutical Co PE ratio based on its reported earnings over the past 12 months is 10.08. The shares last closed at ¥2,310.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Zeria Pharmaceutical Co?
Zeria Pharmaceutical Co's management team is headed by:
- Sachiaki Ibe - CHM
- Mitsuhiro Ibe - PRE
- Hirokazu Endo - VPR
- Makoto Kishimoto - MDR
- Hiroki Kato - DSL
- Kenji Kusano - DSL
- Yuki Okazawa - DHR
- Yoshihiro Hiraga - OTH
- Toshiaki Kawagoe - OTH
- Tetsuo Komori - IND
- Seiji Morimoto - IND
- Kikuo Nomoto - IND